Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
暂无分享,去创建一个
Matthew J. O’Meara | G. Mashour | Tristan Frum | Jessie Huang | S. Handelman | D. Kotton | C. Wobus | K. Alysandratos | J. Spence | Teresa R. O’Meara | C. Mirabelli | K. Weatherwax | Carla D. Pretto | J. Sexton | Namrata S. Kadambi | Charles J. Zhang | J. W. Wotring | S. M. McCarty | Reid Fursmidt | A. Amin | R. Fursmidt
[1] Matthew J. O’Meara,et al. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 , 2021, Proceedings of the National Academy of Sciences.
[2] E. Morrisey,et al. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 , 2021, Cell Reports.
[3] Li Yang,et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs , 2020, Acta Pharmacologica Sinica.
[4] W. L. Jorgensen,et al. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 , 2020, bioRxiv.
[5] Kathleen M. Jagodnik,et al. The COVID-19 Drug and Gene Set Library , 2020, Patterns.
[6] Eytan Ruppin,et al. Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.
[7] Andrew R. Leach,et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.
[8] D. Kell,et al. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria , 2020, Frontiers in Immunology.
[9] Jian-Piao Cai,et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system , 2020, Pharmacological Research.
[10] Kathleen M. Jagodnik,et al. The COVID-19 Gene and Drug Set Library , 2020, Research square.
[11] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[12] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[13] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[14] K. Yamauchi,et al. Antiviral Effects of Bovine Lactoferrin on Human Norovirus. , 2020, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[15] Vasuki H. Dandu,et al. COVID-19 presenting as stroke , 2020, Brain, Behavior, and Immunity.
[16] Yolanda T. Chong,et al. Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2 , 2020, bioRxiv.
[17] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[18] Peter G. Schultz,et al. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals , 2020, bioRxiv.
[19] F. A. Lagunas-Rangel,et al. High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients , 2020, Journal of medical virology.
[20] Rong Lin,et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes , 2020, The American journal of gastroenterology.
[21] K. Hajifathalian,et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant , 2020, World journal of gastroenterology.
[22] C. Tondo,et al. Cardiac and arrhythmic complications in patients with COVID‐19 , 2020, Journal of cardiovascular electrophysiology.
[23] Yan Zhang,et al. Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir , 2020, bioRxiv.
[24] Eugene V. Koonin,et al. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses , 2020, bioRxiv.
[25] H. Shan,et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection , 2020, Gut.
[26] Robert J. Mason,et al. Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.
[27] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[28] Yan Zhao,et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.
[29] David Shum,et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.
[30] P. Conti,et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. , 2020, Journal of biological regulators and homeostatic agents.
[31] Gianpaolo Ronconi,et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. , 2020 .
[32] Dandan Wu,et al. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib , 2020, Journal of Microbiology, Immunology and Infection.
[33] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[34] Bing Han,et al. COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission , 2020, Gastroenterology.
[35] Ivan Griffin,et al. COVID-19: combining antiviral and anti-inflammatory treatments , 2020, The Lancet Infectious Diseases.
[36] H. Shan,et al. Evidence for Gastrointestinal Infection of SARS-CoV-2 , 2020, Gastroenterology.
[37] Ignacio S. Caballero,et al. Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors. , 2020, Cell stem cell.
[38] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[39] Adrian W. R. Serohijos,et al. The Combination of IFN β and TNF Induces an Antiviral and Immunoregulatory Program via Non-Canonical Pathways Involving STAT2 and IRF9 , 2019, Cells.
[40] D. Kotton,et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells , 2019, Nature Protocols.
[41] Keisha N. Hardeman,et al. Quantifying Drug Combination Synergy along Potency and Efficacy Axes. , 2019, Cell systems.
[42] Leland McInnes,et al. UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..
[43] Anne E Carpenter,et al. CellProfiler 3.0: Next-generation image processing for biology , 2018, PLoS biology.
[44] K. Neumann,et al. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial , 2018, BMC Cancer.
[45] K. Garver,et al. Z-FA-FMK demonstrates differential inhibition of aquatic orthoreovirus (PRV), aquareovirus (CSRV), and rhabdovirus (IHNV) replication. , 2018, Virus research.
[46] E. Morrisey,et al. Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. , 2017, Cell stem cell.
[47] J. Ward,et al. Secretoglobin Superfamily Protein SCGB3A2 Alleviates House Dust Mite-Induced Allergic Airway Inflammation in Mice , 2016, International Archives of Allergy and Immunology.
[48] Gui Yang,et al. Hepatitis C Virus Increases Free Fatty Acids Absorption and Promotes its Replication Via Down-Regulating GADD45α Expression , 2016, Medical science monitor : international medical journal of experimental and clinical research.
[49] D. Zamanillo,et al. The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats , 2016, Scientific Reports.
[50] A. Camm,et al. Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity , 2015, PloS one.
[51] T. Fung,et al. Coronavirus infection, ER stress, apoptosis and innate immunity , 2014, Front. Microbiol..
[52] P. Valenti,et al. Lactoferrin prevents LPS-induced decrease of the iron exporter ferroportin in human monocytes/macrophages , 2014, BioMetals.
[53] D. Zamanillo,et al. Effects of the selective sigma‐1 receptor antagonist S1RA on formalin‐induced pain behavior and neurotransmitter release in the spinal cord in rats , 2014, Journal of neurochemistry.
[54] S. Arévalo-Gallegos,et al. Immunomodulatory effects of lactoferrin , 2014, Acta Pharmacologica Sinica.
[55] F. Chisari,et al. Sigma-1 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection , 2013, Journal of Virology.
[56] D. Zamanillo,et al. Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). , 2012, Journal of medicinal chemistry.
[57] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[58] Tudor I. Oprea,et al. Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.
[59] Chengyu Jiang,et al. Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans , 2011, PloS one.
[60] D. Gilliland,et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.
[61] H. Dupont,et al. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] Yíngyún Caì,et al. Suppression of Coronavirus Replication by Inhibition of the MEK Signaling Pathway , 2006, Journal of Virology.
[63] S. Lorch,et al. Metoclopramide for the Treatment of Gastroesophageal Reflux Disease in Infants: A Systematic Review , 2006, Pediatrics.
[64] S. Lemon,et al. Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.
[65] Renji Reghunathan,et al. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome , 2005, BMC Immunology.
[66] W. Evans. Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy , 2004, Therapeutic drug monitoring.
[67] J. Lilleyman,et al. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. , 2001, British journal of clinical pharmacology.
[68] H. Glossmann,et al. High affinity of sigma1‐binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase , 1997, British journal of pharmacology.
[69] J. Arbiser,et al. Clofazimine: a review of its medical uses and mechanisms of action. , 1995, Journal of the American Academy of Dermatology.
[70] W. Huttner,et al. Chlorate--a potent inhibitor of protein sulfation in intact cells. , 1986, Biochemical and biophysical research communications.
[71] J. Heykants,et al. Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers , 1986, Journal of clinical pharmacology.
[72] J. Alpert,et al. Clinical Pharmacokinetics and Efficacy of Amiodarone for Refractory Tachyarrhythmias , 1983, Circulation.
[73] C. Fenselau,et al. Metabolism of clofazimine in leprosy patients. , 1981, Drug metabolism and disposition: the biological fate of chemicals.
[74] B. Delprat,et al. At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor? , 2020, Advances in experimental medicine and biology.
[75] James A. Bednar,et al. HoloViews: Building Complex Visualizations Easily for Reproducible Science , 2015, SciPy.
[76] Thorsten Meinl,et al. KNIME: The Konstanz Information Miner , 2007, GfKl.
[77] D. Gilliland,et al. TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations , 2007 .
[78] P. Yeni. Update on HAART in HIV. , 2006, Journal of hepatology.
[79] J. R. Scotti,et al. Available From , 1973 .
[80] D. Tepper,et al. QT prolongation and the antiarrhythmic efficacy of amiodarone. , 1986, Journal of the American College of Cardiology.